GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Subscribe To Our Newsletter & Stay Updated